EC (Epirubicin, Cyclophosphamide) Followed by T (Docetaxel) Versus ET (Epirubicin, Docetaxel) Followed by X (Capecitabine) as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer Patients
Overview[ - collapse ][ - ]
| Purpose | This is a prospective, randomised phase III trial, to compare the efficacy and safety profiles of two types of adjuvant chemotherapy regimens for HER2 negative, node positive breast cancer patients. Control Arm: This includes 4 cycles of EC 90/600 mg/m2 day 1 every 3 weeks, followed by 4 cycles of T 100 mg/m2 day 1 every 3 weeks. Experimental Arm: This includes 4 cycles of ET 90/75 mg/m2, day 1 every 3 weeks, followed by 4 cycles of capecitabine 1250 mg/m2, twice a day, via oral intake, for 14 days, and then a one-week rest period. Premenopausal women with hormone receptor positive tumours must receive 5 years of tamoxifen after the end of chemotherapy. Postmenopausal women with hormone receptor positive tumours can receive tamoxifen or aromatase inhibitors (or both) after the end of chemotherapy. Patients may receive radiotherapy when clinically indicated. Estimation of the 5-year disease-free survival in the control arm is 72%. The experimental arm is expected to increase the 5-year disease-free survival by 7% (up to 79%). With an alpha error of 0.05 and 80% power, 592 patients per arm are needed. Assuming a 17% post-randomization drop-out, 691 patients per arm are needed. |
|---|---|
| Condition | Breast Cancer |
| Intervention | Drug: epirubicin Drug: docetaxel Drug: capecitabine |
| Phase | Phase 3 |
| Sponsor | Spanish Breast Cancer Research Group |
| Responsible Party | Spanish Breast Cancer Research Group |
| ClinicalTrials.gov Identifier | NCT00129935 |
| First Received | August 11, 2005 |
| Last Updated | February 6, 2007 |
| Last verified | February 2007 |
Tracking Information[ + expand ][ + ]
| First Received Date | August 11, 2005 |
|---|---|
| Last Updated Date | February 6, 2007 |
| Start Date | February 2004 |
| Estimated Primary Completion Date | February 2012 |
| Current Primary Outcome Measures | 5-year disease-free survival |
| Current Secondary Outcome Measures |
|
Descriptive Information[ + expand ][ + ]
| Brief Title | EC (Epirubicin, Cyclophosphamide) Followed by T (Docetaxel) Versus ET (Epirubicin, Docetaxel) Followed by X (Capecitabine) as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer Patients |
|---|---|
| Official Title | Multicenter, Randomized Phase III Trial to Compare Epirubicin and Cyclophosphamide (EC) Followed by Docetaxel (T) to Epirubicin and Docetaxel (ET) Followed by Capecitabine (X) as Adjuvant Treatment for Operable, Node Positive Breast Cancer Patients |
| Brief Summary | This is a prospective, randomised phase III trial, to compare the efficacy and safety profiles of two types of adjuvant chemotherapy regimens for HER2 negative, node positive breast cancer patients. Control Arm: This includes 4 cycles of EC 90/600 mg/m2 day 1 every 3 weeks, followed by 4 cycles of T 100 mg/m2 day 1 every 3 weeks. Experimental Arm: This includes 4 cycles of ET 90/75 mg/m2, day 1 every 3 weeks, followed by 4 cycles of capecitabine 1250 mg/m2, twice a day, via oral intake, for 14 days, and then a one-week rest period. Premenopausal women with hormone receptor positive tumours must receive 5 years of tamoxifen after the end of chemotherapy. Postmenopausal women with hormone receptor positive tumours can receive tamoxifen or aromatase inhibitors (or both) after the end of chemotherapy. Patients may receive radiotherapy when clinically indicated. Estimation of the 5-year disease-free survival in the control arm is 72%. The experimental arm is expected to increase the 5-year disease-free survival by 7% (up to 79%). With an alpha error of 0.05 and 80% power, 592 patients per arm are needed. Assuming a 17% post-randomization drop-out, 691 patients per arm are needed. |
| Detailed Description | Not Provided |
| Study Type | Interventional |
| Study Phase | Phase 3 |
| Study Design | Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment |
| Condition | Breast Cancer |
| Intervention | Drug: epirubicin Drug: docetaxel Drug: capecitabine |
| Study Arm (s) | Not Provided |
Recruitment Information[ + expand ][ + ]
| Recruitment Status | Completed |
|---|---|
| Estimated Enrollment | 1382 |
| Estimated Completion Date | February 2012 |
| Estimated Primary Completion Date | Not Provided |
| Eligibility Criteria | Inclusion Criteria: - Written informed consent. - Histological diagnosis of operable invasive adenocarcinoma of the breast (T1-T3). Tumours must be HER2 negative. Time window between surgery and study randomization must be less than 60 days. - Surgery must consist of mastectomy or conservative surgery with axillary lymph node dissection. Margins free of disease and ductal carcinomas in situ (DCIS) are required. Lobular carcinoma is not considered a positive margin. - Positive axillary lymph nodes defined as at least 1 out of 10 nodes with presence of disease. If sentinel node technique is used, sentinel node can be the only node affected. Patients belonging to the following classifications are eligible: pN1a, pN2a, pN3a. - Status of hormone receptors in primary tumour. Results must be available before the end of adjuvant chemotherapy. - Patients must not present evidence of metastatic disease. Status of HER2 in primary tumour, known before randomization. Patients with immune histochemistry (IHC) 0 or +1 are eligible. For patients with ICH 2+, fluorescence in situ hybridization (FISH) is mandatory and result must be negative. - Age >= 18 and <= 70 years old. - Performance status (Karnofsky index) >= 80. - Normal electrocardiogram (EKG) in the 12 weeks prior to randomization. If needed, normal cardiac function must be confirmed by left ventricular ejection fraction (LVEF). - Laboratory results (within 14 days prior to randomization): - Hematology: neutrophils >= 1.5 x 10^9/l; platelets >= 100 x 10^9/l; hemoglobin >= 10 mg/dl; - Hepatic function: total bilirubin <= 1 upper normal limit (UNL); SGOT and SGPT <= 2.5 UNL; alkaline phosphatase <= 2.5 UNL. If values of SGOT and SGPT > 1.5 UNL are associated to alkaline phosphatase > 2.5 UNL, patient is not eligible; - Renal function: creatinine <= 175 mmol/l (2 mg/dl); creatinine clearance >= 60 ml/min; - Pharmacogenetics: one blood sample is needed for SNP assessment. - Complete stage workup during the 12 weeks prior to randomization (mammograms are allowed within a 20 week window). All patients must have a bilateral mammogram, thorax x-ray, abdominal echography and/or computed tomography (CT)-scan. If bone pain, and/or alkaline phosphatase elevation, a bone scintigraphy is mandatory. This test is recommended for all patients. Other tests: as clinically indicated. - Patients able to comply with treatment and study follow-up. - Negative pregnancy test done in the 14 prior days to randomization. Exclusion Criteria: - Prior systemic therapy for breast cancer. - Prior therapy with anthracyclines or taxanes (paclitaxel or docetaxel) for any malignancy. - Prior radiotherapy for breast cancer. - Bilateral invasive breast cancer. - Pregnant or lactating women. Adequate contraceptive methods must be used during chemotherapy and hormone therapy treatments. - Any T4 or M1 tumour. - Axillary lymph nodes: patients belonging to the following classifications are excluded: pN1b, pN1c, pN2b, pN3b, pN3c. - HER2 positive breast cancer (IHC 3+ or positive FISH result). - Pre-existing grade >= 2 motor or sensorial neurotoxicity (National Cancer Institute Common Toxicity Criteria version 2.0 [NCI CTC v-2.0]). - Any other serious medical pathology, such as congestive heart failure; unstable angina; history of myocardial infarction during the previous year; uncontrolled HA or high risk arrhythmias. - History of neurological or psychiatric disorders, which could preclude the patients from free informed consent. - Active uncontrolled infection. - Active peptic ulcer; unstable diabetes mellitus. - Previous or current history of neoplasms different from breast cancer, except for skin carcinoma, cervical in situ carcinoma, or any other tumour curatively treated and without recurrence in the last 10 years; ductal in situ carcinoma in the same breast; lobular in situ carcinoma. - Chronic treatment with corticosteroids. - Contraindications for corticosteroid administration. - Concomitant treatment with raloxifene, tamoxifen or other selective estrogen receptor modulators (SERMs), either for osteoporosis treatment or for prevention. These treatments must stop before randomisation. - Concomitant treatment with other investigational products; participation in other clinical trials with a non-marketed drug in the 20 previous days before randomization. - Concomitant treatment with another therapy for cancer. - Males. |
| Gender | Female |
| Ages | 18 Years |
| Accepts Healthy Volunteers | No |
| Contacts | Not Provided |
| Location Countries | Spain |
Administrative Information[ + expand ][ + ]
| NCT Number | NCT00129935 |
|---|---|
| Other Study ID Numbers | GEICAM 2003-10 |
| Has Data Monitoring Committee | Not Provided |
| Information Provided By | Spanish Breast Cancer Research Group |
| Study Sponsor | Spanish Breast Cancer Research Group |
| Collaborators | Sanofi Hoffmann-La Roche Pfizer |
| Investigators | Study Chair: Miguel Martín, MD., PhD. Spanish Breast Cancer Research Group (GEICAM) |
| Verification Date | February 2007 |
Locations[ + expand ][ + ]
| Spanish Breast Cancer Research Group (GEICAM) | San Sebastián de los Reyes, Madrid, Spain, 28700 |
|---|